

Mar
2023



Co-Dx

Rx only

Logix Smart™
Coronavirus Disease
2019 (COVID-19) Kit

For use under the Emergency use Authorization (EUA) only
For *in vitro* diagnostic use

REF

COVID-K-001

LOGIX SMART™ Coronavirus Disease 2019 (COVID-19) Kit
CO-DIAGNOSTICS, INC.

CO-DIAGNOSTICS, INC. | 2401 Foothill Dr., Ste D, Salt Lake City, UT 84109 USA

CE

IVD



Table of Contents

1	INTENDED USE	3
2	PRODUCT DESCRIPTION AND TEST PRINCIPLE	3
2.1	Principles of Operation	4
3	STORAGE AND HANDLING	6
4	MATERIAL REQUIRED BUT NOT INCLUDED WITH THE TEST.....	6
4.1	Consumables Required but Not Provided.....	7
4.2	Equipment Required but Not Provided	7
5	WARNINGS AND PRECAUTIONS	7
6	SAMPLE COLLECTION, TRANSPORT, AND STORAGE.....	8
6.1	Lower Respiratory Tract Fluids	8
6.2	Upper Respiratory Tract Fluids	9
6.3	Sample Handling	9
6.4	Sample Storage	9
6.5	Sample Shipping.....	10
7	PROCEDURE	10
7.1	Sample Preparation	10
7.2	Logix Smart COVID-19 Reagent Setup.....	11
7.3	Reaction Set Up.....	11
7.4	PCR Instrument Setup for the CoDx Box.....	12
8	DATA ANALYSIS.....	13
8.1	Analysis Settings.....	13
8.2	Positive Controls	14
8.3	Negative Control	15
8.4	The Validity of the Diagnostic Test Runs.....	15
8.5	Interpretation of Results.....	15
9	TROUBLESHOOTING	17
9.1	Stability	17
9.2	User Errors	17
9.3	Invalid Results	17



10	LIMITATIONS.....	19
11	CONDITIONS OF AUTHORIZATION FOR THE LABORATORY.....	20
12	NON-CLINICAL PERFORMANCE EVALUATION	21
12.1	Limit of Detection (LoD) – Analytical Sensitivity.....	21
12.2	Inclusivity (Analytical Sensitivity).....	22
12.3	Cross-Reactivity (Analytical Specificity) By an In Silico Analysis	25
12.4	Microbial Interference	28
13	CLINICAL EVIDENCE	28
14	MANUFACTURER AND AUTHORIZED REPRESENTATIVE.....	29
15	REFERENCES.....	29
16	LEGEND OF PACKAGE SYMBOLS	31

1 INTENDED USE

The **Logix Smart™ Coronavirus Disease 2019 (COVID-19)** test is a real-time RT-PCR test intended for the in vitro qualitative detection of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in lower respiratory tract fluids (e.g. bronchoalveolar lavage, sputum, tracheal aspirate), and upper respiratory tract fluids (e.g. nasopharyngeal and oropharyngeal swabs) from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in lower respiratory tract fluids (e.g. bronchoalveolar lavage, sputum, tracheal aspirate), and upper respiratory tract fluids (e.g. nasopharyngeal and oropharyngeal swabs) during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The Logix Smart Coronavirus Disease 2019 (COVID-19) is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The **Logix Smart Coronavirus Disease 2019 (COVID-19)** test is only for use under the Food and Drug Administration's Emergency Use Authorization.

2 PRODUCT DESCRIPTION AND TEST PRINCIPLE

The **Logix Smart Coronavirus Disease 2019 (COVID-19)** test is a real-time, reverse transcription polymerase chain reaction (rRT-PCR) test utilizing the Company's patented CoPrimer™ technology (Satterfield, 2014) (Poritz & Ririe, 2014). The SARS-CoV-2 CoPrimer sets are designed to detect RNA from SARS-CoV-2 in lower respiratory tract fluids (e.g., bronchoalveolar lavage, sputum, tracheal aspirate) and upper respiratory tract fluids (e.g., nasopharyngeal and oropharyngeal swabs) from patients who are suspected of COVID-19 by a healthcare provider.

Each **Logix Smart COVID-19** test kit consists of the following components:

- Ready-to-use Master Mix, complete with RNaseP internal positive control (to verify sample quality)
- Positive Control (PC), to verify the performance of the master mix
- Nuclease-Free Water as a negative control (to verify the master mix is free of contamination)

2.1 Principles of Operation

The test begins with the selection of the sample type, followed by a collection of the sample by a trained healthcare provider. The sample must be identified following the laboratory quality system and current regulation. The sample must be stored properly until testing in the same facility or shipping to the assigned laboratory.

The Logix Smart COVID-19 test kit assay is a multiplexed, single-step, real-time reverse transcription PCR test that can be broken down into the following three stages:

- Sample preparation
- Reverse transcription
- Polymerase chain reaction (PCR) with real-time monitoring

Note: The assay also includes an internal positive control (IPC) that acts as an extraction control to confirm the performance of the extraction.

The sample preparation for PCR requires the samples to be processed to break apart cells and viruses to expose the genetic material. For this process, a commercially available extraction system is used. In this process, the nucleic acids are isolated and purified from the lower respiratory tract fluids (e.g., bronchoalveolar lavage, sputum, tracheal aspirate), or the upper respiratory tract fluids (e.g., nasopharyngeal and oropharyngeal swabs) using the QIAamp Viral RNA Mini Kit (Qiagen) using the protocol outlined in the product's handbook, "Protocol: Purification of Viral RNA (Spin Protocol)" using 140 µL of the lower respiratory tract fluids (e.g., bronchoalveolar lavage, sputum, tracheal aspirate) or the upper respiratory tract fluids (e.g., nasopharyngeal and oropharyngeal swabs). In the case of sputum samples, the sample should be treated before the extraction by the CDC's guidelines for Processing of Sputum Specimens for Nucleic Acid Extraction (CDC, 2020).

The purified nucleic acid is then plated with the Logix Smart Coronavirus Disease 2019 (COVID-19) master mix, 5 µL of each. The master mix is pre-mixed and contains the necessary components to perform both the reverse transcription and PCR. This eliminates the need for master mix to be prepared ahead of time by the user.

The plated reactions will then be put in the thermocycler using the following cycling conditions:

- 15 minutes at 45°C
- 2 minutes at 95°C
- 50 cycles x [3s at 95°C, 32s at 55°C]

Note: The 15-minute step at 45°C is the reverse transcription step, where the cDNA is created from the RNA template.

The 2 minute step at 95°C is to inactivate the reverse transcriptase and acts as the initial denaturation step for PCR, which is then followed by the thermocycling for the PCR.

During the PCR, the FAM labeled forward CoPrimer acts as both the forward primer and the probe. During the annealing/extension phase of the PCR, the 5' nuclease activity of Taq polymerase degrades the CoPrimer's portion that has annealed to the targeted sequence, causing spatial separation between the fluorophore and the quencher, generating a fluorescent signal. With each cycle, additional fluorophore molecules are cleaved from their respective probes, increasing the fluorescence intensity. Fluorescence intensity is monitored at the end of each cycle by the real-time thermocycler, specifically the CoDx Box™.

Components included in the test kit are displayed in Table 1.

Table 1

Components Included in the Test Kit

Cap Color	Component	Symbol	Individual Catalog Number	Description	Amount
Brown	Logix Smart COVID-19 Master Mix	MM	COVID-MM-001	Proprietary blend of SARS-CoV-2 CoPrimers and PCR reagents	1 × 500µL (100 reactions) or 1 × 1,250µL (250 reactions) or 1 × 25,000µL (5,000 reactions)
Red	Logix Smart COVID-19 Positive Control	PC	COVID-PC-001	Proprietary blend of SARS-CoV-2 synthetic templates	1 × 500µL (100 reactions) or 1 × 1,250µL (250 reactions) or 1 × 25,000µL (5,000 reactions)
Clear	Nuclease Free Water	NTC	GEN-NF-001	Water free of DNase/RNase activity	1 × 500µL (100 reactions) or 1 × 1,250µL (250 reactions) or 1 × 25,000µL (5,000 reactions)

3 STORAGE AND HANDLING

The following list includes important storage and handling information:

- The **Logix Smart COVID-19 kit** is shipped on dry ice. The components of the kit should arrive frozen. If one or more of the components are not frozen upon receipt or are compromised during shipment, contact your distributor for assistance.
- All components should be stored immediately at or below -20°C to prevent degradation of reagents.
- Always work with each **Logix Smart COVID-19** component on ice. Make aliquots, if necessary, to avoid multiple freeze/thaw cycles.
- If you work in an area prone to power outages, ensure you have a back-up generator for your freezer and a temperature data log to ensure that the **Logix Smart COVID-19 kit** remains frozen at -20°C.
- Stability data for the product is currently being collected and results will be published, and new Instructions for Use updated to reflect the stability conditions.

4 MATERIAL REQUIRED BUT NOT INCLUDED WITH THE TEST

Extraction systems required but not included with the test are displayed in Table 2 and Table 3.

Table 2

Extraction Systems Validated with the Test

Extraction System Options	Catalog Number	Manufacturer
QIAamp Viral RNA Mini Kit	52904 (50 extractions) 52906 (250 extractions)	Qiagen

Table 3

Thermocyclers Validated but Not Included with the Test

Thermocycler Machine	Manufacturer
CoDx Box	BMS, Bio Molecular Systems

4.1 Consumables Required but Not Provided

- Disposable powder-free gloves and lab coats
- Disposable pipette tips with filters
- A 10% bleach or other appropriate cleaning solution that degrades nucleic acids
- PCR plates or strip tubes for the thermocycler being used

4.2 Equipment Required but Not Provided

- Several micropipettes capable of pipetting volumes from 5 µL to 1,000 µL
- A cold block or ice
- A vortex and centrifuge
- A Class II Biosafety cabinet, ideally in a BSL-2 containment facility, for the extraction
- A PCR workstation, for master mix plating and setup
- A CoDx Box (Bio Molecular Systems, distributed by Co-Diagnostics, Inc.)

5 WARNINGS AND PRECAUTIONS



WARNING!

Before performing any testing or running any patient sample, verify that all instruments have been properly installed, calibrated, and are well maintained. Do **not** use instruments with an outdated calibration.

As with any diagnostic or laboratory experiment, good laboratory practices for molecular biology is essential to the proper performance of the qPCR or any laboratory experiment. Attention should be taken to the procedures specific to molecular diagnostics.

Due to the high sensitivity of the **Logix Smart COVID-19** test and the qPCR technology, handle samples and materials with care while performing the assay to keep reagents and amplification mixtures free of contamination. Users should pay attention to the following:

- Use sterile pipette tips with filters.
- Use standard precautions when handling any patient samples, as they may contain infectious agents.
- Store and extract positive materials (specimens, positive controls, and amplicons) separately from other reagents.
- Always use nuclease-free water provided with this kit.
- Consult appropriate Safety Data Sheets (SDS) for instructions on safe use. The

SDS for the **Logix Smart COVID-19** test kit is provided with the shipment. If not provided with the shipment, the SDS can be retrieved from Co-Diagnostics website at the following link: <http://co-dx.com/products/diagnostic-solutions/>.

- To prevent contamination, it is required to use Good Laboratory Practices for Molecular Biology, which requires a unidirectional workflow and the separation of negative and positive materials.
- Always use the most recent version of this document as more information is added with future studies. This can be downloaded for free at the following link: <http://co-dx.com/resources/instructions-for-use/>.

6 SAMPLE COLLECTION, TRANSPORT, AND STORAGE

Sample selection, collection, storage, and handling play an essential part in the performance of nucleic acid assays. Valuable information is presented here to help laboratories develop better procedures for the analysis of results and troubleshooting other problems.

For more information, visit the CDC's and WHO's websites at the following addresses:

- CDC - <https://www.cdc.gov/coronavirus/2019-nCoV/lab/index.html>
- WHO - <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance>

6.1 Lower Respiratory Tract Fluids

- 6.1.1 **Bronchoalveolar lavage, tracheal aspirate:** Collect 2-3 mL into a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container. Refrigerate specimen at 2-8°C and ship overnight to the testing laboratory on an ice pack.
- 6.1.2 **Sputum:** Have the patient rinse their mouth with water and then expectorate deep cough sputum directly into a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container. Refrigerate the specimen at 2-8°C and ship overnight to the testing laboratory on an ice pack.

6.2 Upper Respiratory Tract Fluids

- 6.2.1 **Nasopharyngeal swab AND oropharyngeal swab (NP/OP swab):** Use only synthetic fiber swabs with plastic shafts. Do not use calcium alginate swabs or swabs with wooden shafts, as they may contain substances that inactivate some viruses and inhibit PCR testing. Place swabs immediately into sterile tubes containing 2-3 mL of viral transport media. NP and OP specimens should be kept in separate vials. Refrigerate the specimen at 2-8°C and ship overnight to the testing laboratory on an ice pack. Note: Nasopharyngeal swab: Insert a swab into the nostril parallel to the palate. Leave the swab in place for a few seconds to absorb secretions/ Swab both nasopharyngeal areas with the same swab.
- 6.2.2 **Oropharyngeal swab (e.g., throat swab):** Swab the patient's posterior pharynx, avoiding the tongue.
- 6.2.3 **Nasopharyngeal wash/aspirate or nasal aspirate:** Collect 2-3 mL into a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container. Refrigerate the specimen at 2-8°C and ship overnight to the testing laboratory on an ice pack.

6.3 Sample Handling

Laboratory workers should wear appropriate personal protective equipment (PPE), including disposable gloves, laboratory coat/gown, and eye protection when handling potentially infectious specimens.

Clinical specimens from patients suspected or confirmed to be infected with COVID-19 should be conducted under a certified Class II biosafety cabinet in a BSL-2 containment facility. More details are provided in the *Biosafety in Microbiological and Biomedical Laboratories (BMBL)* (CDC, 2009) or the *WHO Laboratory Biosafety Manual* (WHO, 2004).

For specific instructions on handling clinical specimens for coronavirus disease 2019, see the CDC's webpage for the *Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)* (CDC, 2020).

6.4 Sample Storage

Specimen types can be kept at -20°C for up to 7 days. For storage longer than 7 days, freeze specimens at -70°C. Avoid repeated freezing and thawing of a specimen. If a specimen is kept for retesting, aliquot the specimen in different tubes to avoid freezing and thawing cycles. Monitor the temperature in the storage areas and record the temperature regularly to identify potential fluctuations. Domestic refrigerators or freezers with wide temperature fluctuations are not suitable for the storage of frozen specimens (CDC, 2020).

6.5 Sample Shipping

Specimens known to be, or suspected of, containing SARS-CoV-2 that require shipment by air should be shipped on dry ice as a Biological Substance Category B, UN3373. International regulations, as described in the WHO Guidance on Regulations for the Transport of Infectious Substances 2015-2016, should be followed (CDC, 2020). If ground transportation is needed, ship the specimen frozen overnight with enough ice to keep it frozen throughout the entire transit. After it is collected and transferred to the clinical lab, the sample will receive an entry into the laboratory system.

7 PROCEDURE

The WHO recommends recording the full name, date of birth, contact information, and the time and date of collection of the patient sample. Additionally, the following information could be collected:

- Symptoms, date of onset, duration of symptoms, contact with known COVID-19 cases (e.g., family member)
- Comprehensive travel history (dates, place, duration of visit)

7.1 Sample Preparation

The quality of the RNA from the extraction of the sample is essential to the performance of **Logix Smart COVID-19**. The extraction protocol should be performed following the manufacturer's instructions. However, due to the mucoid and mucopurulent, and therefore, the viscous nature of sputum specimen, a pre-processing of the sample is recommended before extraction. A protocol provided by the CDC and evaluated for COVID-19 for the processing of sputum samples is available by the CDC in the following link: <https://www.cdc.gov/coronavirus/2019-ncov/downloads/processing-sputum-specimens.pdf> (CDC, 2020).

Follow these steps when preparing a sputum sample:

- 7.1.1 Create a fresh 500 mM final concentration Dithiothreitol (DTT) solution.

Note: The DTT needs to be freshly prepared.

- 7.1.2 Discard any unused DTT solution.

- 7.1.3 Add 100 µL of the freshly prepared DTT solution to 5 mL of cold sterile 0.01 M PBS (pH 7.2) and mix briefly.

- 7.1.4 In a microcentrifuge tube, add an equal volume of diluted DTT-PBS solution and sputum specimen (e.g., 140 µL of sputum + 140 µL of DTT-PBS solution).

Note: The volumes can be scaled based on the number of sputum samples

that will be processed.

- 7.1.5 Incubate the sample, mixing occasionally, at room temperature until the sample is liquified (This may take up to 30 minutes).
- 7.1.6 Use the liquified sample for downstream nucleic acid extraction, following the extraction system manufacturer's guidelines. Retain any residual liquified sample at -80°C.

Note: Extraction of RNA using the QIAamp® Viral RNA Mini Kit must be performed following the manufacturer's instructions using 140 µL of the sample, and a modified elution using 100 µL of buffer AVE. To ensure the removal of residual wash buffer from the sample prior to elution, do an additional centrifugation step using a new collection tube (see extraction procedure).



Wash buffers used in the extraction kit contain ethanol. It is important to eliminate any traces of ethanol before elution of the nucleic acid. Ethanol is a strong inhibitor of real-time PCR.

7.2 Logix Smart COVID-19 Reagent Setup

Follow these steps to setup the reagent:

- When preparing reagents, clean all working surfaces with a fresh 10% bleach solution followed by molecular-grade alcohol or another equivalent method of cleaning that disinfects and degrades nucleic acids.
- Vortex all **Logix Smart COVID-19** Master Mix, Positive Control (PC), nuclease-free water (used as a no template control or NTC), and sample tubes for 3 seconds and briefly spin down before using to ensure properly mixed reagents and to remove any condensation or residue from the lids.
- Thaw all reagents and samples on **ice**, or a cold block, before starting setup.

7.3 Reaction Set Up

- 7.3.1 Set up each reaction to include enough reaction wells for the number of patient samples, at least one positive control, and one NTC (# patient samples + 2 = total reaction wells needed). [e.g., 5 patient samples to test + 1 PC well + 1 NTC well = 7 total reaction wells].
- 7.3.2 Do all pipetting on ice, if possible. It is recommended that pipetting PC and performing sample elution is done in a separate area, or at a separate time, from Master Mix and NTC. Also, change pipette tips between patient sample

elutions and change pipette tips after pipetting each component. Pipet the PC last, if possible, to avoid contamination events.

- 7.3.3 Pipet 5 μ L of **Master Mix** into each well being used in an appropriate optical plate or optical reaction tube (e.g., CoDx Box real-time PCR instrument uses 48-well reaction tubes).
- 7.3.4 Pipet 5 μ L of the patient sample (elution from nucleic acid extraction) or 5 μ L of a control (NTC and PC) to the appropriate well(s). Ensure that at least one positive control and one NTC control is included in each run.
- 7.3.5 Seal the reaction plate with an optical adhesive film or the reaction tubes with appropriate lids.
- 7.3.6 Place the plate or tubes into the real-time PCR instrument in the correct orientation and start the run.

7.4 PCR Instrument Setup for the CoDx Box

- 7.4.1 Contact the Laboratory 801-438-1036 ext. 03 or at www.co-dx.com/contact/ for the template file for download. The template file comes pre-programmed with the PCR instrument setup described in this section. When not using a template, use the settings outlined below to program the CoDx Box PCR instrument.
- 7.4.2 Define the settings displayed in Table 4.

Table 4

PCR Instrument Settings

Item	Setting
Reaction Volume	10 μ L
Ramp Rate	Default
Passive Reference	None

- 7.4.3 Program PCR instrument with the cycling conditions displayed in Table 5.

Table 5

Programs for PCR Instrument Cycling Conditions

Stage	Cycles	Temperature	Time
Reverse Transcription	1	45°C	15 minutes
Initial Denature	1	95°C	2 minutes
Amplification	50	95°C	3 seconds
		55°C	32 seconds

7.4.4 Define the fluorescence detectors (dyes) displayed in Table 6.

Table 6

Definitions for Fluorescence Detectors (Dyes)

Target	Detector Name	Reporter	Quencher
COVID-19 specific RNA	COVID-19	FAM™	BHQ® - 1
RNaseP specific DNA (IPC)	RNaseP	CAL Flour® Red 610	BHQ® - 2

7.4.5 When the run is finished, ensure that the run file is saved.

8 DATA ANALYSIS

Verification and validation studies performed for **Logix Smart Coronavirus Disease 2019 (COVID-19) (COVID-K-001)** were conducted following Good Laboratory Practices for Molecular Biology assays (Viana & Wallis, 2011). If these conditions are not met, the performance will display higher variability, due to user errors while experimenting.

8.1 Analysis Settings

The analysis parameters on the CoDx Box should be set to the following, but after every run, the settings for both the green channel (monitoring for COVID-19), and the orange channel (monitoring for RNaseP [IPC]), should be verified. To do this, perform the following steps:


- Check the **Auto Set Threshold** checkbox.
- Set **Method** to Dynamic.
- Set **Threshold Level** to 0.100.
- Set **Threshold Start** to 1.00.
- Set **Ignore Cycles Before** to 5.
- Set **Exclusion** to Extensive.
- Set **Fluorescence Cutoff Level** to 5.0%.
- Set **Initial Y-Axis Scale** to Linear.
- Check the box to **Auto Generate Analysis**.

8.2 Positive Controls

Highlight the positive control reaction well. Each positive control should display an amplification curve for the COVID-19 marker in the FAM channel and amplification of the internal positive control for RNaseP (IPC) in the CF610 channel. A positive amplification curve looks like the purple curve in Figure 1 and should have a Cq value below 45 cycles.

Figure 1

Positive Control (PC) and No Template Control (NTC) Amplification for Logix Smart COVID-19



8.3 Negative Control

Next, highlight the negative control. The results of the negative control should show no amplification, specifically with a Cq value less than 45. An example of no amplification can be seen in Figure 1, as the red line, which is below the threshold area (the grey band with the red line).

8.4 The Validity of the Diagnostic Test Runs

Check to see that both the positive and no template control have passed.

8.4.1 Ensure the control conditions outlined in Table 7 are met.

Table 7

Control Conditions

Control Type	Control Name	Purpose of Control	COVID-19 FAM channel	Internal Control (RNaseP) CF610 channel
COVID-19 Positive Control	COVID-19 (FAM™)	Verifies the performance of the master mix	+	+
	RNaseP (CF@610)			
No Template Control	Master Mix + Water	Verifies the reagents are free of contamination	-	-

8.4.2 If controls pass, interpret the sample results.

8.4.3 If any of the controls fail, the run is invalid. Document the run and initiate troubleshooting.

8.5 Interpretation of Results

Once the controls have passed, the unknown samples can be interpreted based on three possible outcomes:

- Positive
- Negative
- Invalid

A **Positive** result will display an amplification curve or cycle threshold value for COVID-19 at or below 45 cycles. Amplification curves greater than 45 cycles for COVID-19 are in the uncertainty zone. The presence of a curve, with a Cq at or below 45 cycles, for a sample in the COVID-19, indicates a positive result. The amplification of the RNaseP (IPC) displays that the extraction was successful.

A **Negative** result will display no amplification for COVID-19 coronavirus; however, occasionally amplification greater than 45 cycles may occur in COVID-19 or RNaseP channels. Any amplification curves greater than 45 cycles for COVID-19 are in the uncertainty zone and could be below the limit of detection. Consider performing a new run of the same sample or another sample from the patient during the following days. The absence of a curve for COVID-19 indicates a negative result **ONLY** when the RNaseP (IPC) marker is positive.

An **Invalid** result refers to situations when any of the controls fail. See the Troubleshooting section for details.

Translate the interpretation of results with Ct values according to Table 8.

Table 8

Interpretation of Results for COVID-19 by Detection of SARS-CoV-2 RdRp Gene with Logix Smart COVID-19

	Sample Result		Logix Smart COVID-19 Positive Control	No Template Control (NTC) (Master Mix + Water)	Interpretation of Results
	COVID-19 (SARS-CoV-2)	Internal Positive Control (RNaseP) CF610 channel			
Instrument Reading	+	+	+	-	SARS-CoV-2 RNA +
	-	+	+	-	SARS-CoV-2 RNA -
	Any Result (+/-)	-	+	-	INVALID: See Troubleshooting
		+	-	-	
		+	+	+	

Anything before 45 cycles is considered a positive reading (+). Anything after 45 cycles is considered a negative reading (-). When possible, always check that the medical history and/or symptoms match the result before treatment.

9 TROUBLESHOOTING

Co-Diagnostics Inc. values customer feedback and wants to be informed of any issues with the **Logix Smart COVID-19** test kit, even if the recommended steps for troubleshooting solves the issue. To give feedback, please fill out the Customer Feedback Form by visiting www.co-dx.com/contact/feedback/.

9.1 Stability

Real-time, accelerated shelf-life, and in-use stability studies are currently under testing. Currently, the expiration date of this product has been established as 12 months.

Always use the most recent version of this document for updates as more stability information will be added when studies are completed.

9.2 User Errors

The Polymerase Chain Reaction (PCR) assay is a technique that uses temperature cycling, and a DNA polymerase to amplify a single copy or a few copies of a segment of DNA or RNA. Always use Good Laboratory Practices for Molecular Biology Diagnostics (Viana & Wallis, 2011) when using this product. This product is not intended to be used by untrained personnel.

The user needs to have some molecular biology experience and needs to be familiar with the proper pipetting technique to prevent errors, such as splashes, crossover contamination, and errors on volume selection.

Pipette tips must be replaced after every pipetting. Gloves must be replaced often. Equipment must have calibration up to date for the pipettes and thermocyclers, when applicable.

A 90-minute online training for Good Laboratory Practices for Molecular Genetics Testing (Centers for Disease Control and Prevention, 2017) is available at the CDC website at the following link <https://www.cdc.gov/labtraining/training-courses/good-lab-practices-molecular-genetics-testing.html>.

9.3 Invalid Results

Invalid results include one or more of the following:

9.3.1 Logix Smart COVID-19 Positive Control not amplifying

9.3.2 No amplification from the PC could be the result of one or multiple factors, such as the following:

- Pipetting errors (pipetting control into the wrong well, missing a well, pipetting inadequate amount of reagent)

- Incorrect placement of plates or tubes into the real-time PCR instrument
- **Logix Smart COVID-19 Master Mix** or **Logix Smart COVID-19 Positive Control** degradation (a result of reagents being at temperatures above -20°C for an extended period)
- The use of an expired reagent
- The use of the wrong reagents

Without further evidence, the run should be considered invalid and the user should re-test by re-amplification. If the positive control fails again, then an investigation should be conducted to identify possible causes for error and depending on the investigation results and risks identified in the process, the patient samples may need to be re-extracted. If the positive control fails a third time after re-extraction and re-amplification, open a new **Logix Smart COVID-19 Positive Control** or **Master Mix**, and retest. If the positive control fails a fourth time, please contact Co-Diagnostics Inc. Technical Support by calling 801-438-1036 ext. 02 or contact us at www.co-dx.com/contact/.

9.3.3 **RNaseP (IPC)** Not Amplifying in Patient Samples

A no-amplification result from the RNaseP channel could be the result of one or multiple factors, such as the following:

- There was not enough nuclear material in the patient sample.
- PCR inhibitors such as ethanol and heparin were present.
- Extraction was performed incorrectly.
- The extraction kit used was not compatible or has a step that eliminates RNaseP DNA.

Note: Positive amplification in the COVID-19 channel indicates a positive reading despite the lack of concurrent amplification in the IPC channel.

The IPC amplification is dependent on the presence of human genomic DNA (gDNA) in the extraction sample, the amount of which is governed by the type of the patient sample and the extraction procedure used.

Samples obtained from culture or sterile/pure sites (e.g., CSF, urine, cell lysates, etc.) may not contain the human RNaseP gene.

The results should be interpreted as invalid, and re-testing by re-amplification should be performed. If the IPC fails again, then samples should be re-extracted and re-amplified. If it fails a third time an investigation should be conducted to identify possible causes for the error. If the cause for the error is

clear, the test can either be singled out as invalid, due to either PCR inhibitors being present, or not enough nuclear material being present. If the cause for an error is unclear, contact Co-Diagnostics Inc. Technical Support by calling 801-438-1036 ext. 02 or contact us at www.co-dx.com/contact/.

9.3.4 **No Template Control** Shows Amplification

Amplification of COVID-19 in the No Template Control indicates contamination of one or more of the reagents, incorrect placement of plate or tube into the real-time PCR instrument, or pipetting errors.

The results should be interpreted as invalid, and re-testing by re-amplification should be performed. If the NTC fails again, then an investigation should be conducted to identify possible causes for error and depending on the investigation results and risks identified in the process, the patient samples may need to be re-extracted.

If failure of the NTC, after re-extraction and re-amplification, happens a third time, open a new nuclease-free water and retest. If it still fails, the run should be interpreted as invalid. Please contact Co-Diagnostics Inc. Technical Support by calling 801-438-1036 ext. 02 or at: www.co-dx.com/contact/.

10 LIMITATIONS

Limitations include the following:

- Strict compliance with this document is required for optimal results. Always use the most recent version of this document. This can be downloaded for free at www.co-dx.com/resources/instructions-for-use/.
- The use of this product is to be limited to trained and instructed personnel in real-time PCR techniques and IVD procedures.
- Good laboratory practices are essential for the proper performance of this assay. It is also recommended that upon receipt of reagents, a test run be performed to check the performance of the reagents before testing on patient samples.
- Appropriate specimen collection, transport, storage, and processing procedures are required for optimal results.
- Do not use the **Logix Smart COVID-19** kit components directly on the specimens collected. Perform an appropriate nucleic acid extraction before using this assay.
- The presence of PCR inhibitors may cause false negatives or invalid results.
- Potential mutations of the target regions of the COVID-19 genome covered by this test kit may fail to detect the presence of the pathogens.
- As with any diagnostic test, results of the **Logix Smart COVID-19** kit are to be interpreted with consideration of all clinical and laboratory findings.

- The performance of this test was established based on the evaluation of a limited number of clinical specimens. Clinical performance has not been established with all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which changes over time.

11 CONDITIONS OF AUTHORIZATION FOR THE LABORATORY

The **Logix Smart COVID-19** Letter of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients, and authorized labeling are available on the FDA website: <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>. However, to assist clinical laboratories using **Logix Smart COVID-19** (“your product” in the conditions below), see the following relevant Conditions of Authorization:

- Authorized laboratories¹ using your product will include with result reports of your product, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized laboratories using your product will use your product as outlined in the Instructions for Use. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.
- Authorized laboratories that receive your product will notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- Authorized laboratories using your product will have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- Authorized laboratories will collect information on the performance of your product and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and Co-Diagnostics Inc. (phone: +1-801-438-1036 / info@co-dx.com) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of your product of which they become aware.
- All laboratory personnel using your product must be appropriately trained in RT-PCR techniques and use appropriate laboratory and personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.
- Co-Diagnostics Inc., authorized distributors, and authorized laboratories using your product will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

¹ The letter of authorization refers to, “United States (U. S.) laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests” as “authorized laboratories.”

12 NON-CLINICAL PERFORMANCE EVALUATION

The analytical evaluation of performance was performed with contrived samples produced by spiking in a Genomic RNA of SARS-CoV-2, isolate USA-WA1/2020 (BEI Resources, catalog number NR-52285) in a negative clinical matrix of mainly sputum, bronchoalveolar lavage (BAL), nasopharyngeal fluid, and nasal swab samples acquired from Discovery Life Sciences or donations.

12.1 Limit of Detection (LoD) – Analytical Sensitivity

The Limit of Detection (LoD) refers to the lowest concentration of analyte that is detected at a rate of no less than 95%.

The experiment was performed using genomic RNA of SARS-CoV-2, isolate USA-WA1/2020 (BEI Resources, catalog number NR-52285), which was spiked into sputum samples after the lysis step of the QIAamp Viral RNA Mini Kit (Cat# 52904), to prevent degradation of the RNA before the lysis. The extractions were performed using the QIAcube instrument, with 140 µL of the contrived sample and a 100 µL elution. The extractions were spiked with 10,000; 5,000; 1,000; 600; and 50 total copies after the lysis step. After the extraction process, the extracts were then tested using the **Logix Smart COVID-19** test kit protocol. The LoD was confirmed by running at least 20 replicates, at the LoD concentration, which was determined to be 600 total copies. See Table 9 for detailed information.

Table 9

Genomic RNA Strain SARS-CoV-2 (Isolate USA-WA1/2020) Detection Rate in Sputum

Total Concentration/ Sample	# of Samples	# of Detected	Detection Rate (%)	Average Cq	SD (Standard Deviation)	CV% (Coefficient of Variance)
10,000 copies	16	16	100.00	31.55	0.31	0.98
5,000 copies	16	16	100.00	32.22	0.26	0.82
1,000 copies	16	16	100.00	35.06	0.83	2.36
600 copies	16	16	100.00	35.30	0.73	2.08
50 copies	16	1	6.25	38.22	-	-
Positive Control (PC)	2	2	100.00	26.80	0.10	0.38
Nuclease-Free Water	6	0	0	0	0	0
Negative extraction (Blank)	8	0	0	0	0	0

After the runs were completed, 600 total copies (4.29 copies/μL in the patient sample) was the lowest concentration with at least a 95% detection rate. Twenty-one replicates, spiked at 600 total copies, were run. The results of that run are displayed in Table 10.

Table 10

Confirmation of the LoD

Total Copies/Sample	# of Samples	# of Detected	Detection Rate (%)	Average Cq	SD (Standard Deviation)	CV% (Coefficient of Variance)
600 copies	21	21	100.00	35.75	0.66	1.85

The Limit of Detection (LoD) was confirmed to be 600 total copies in 140 μL of sputum, which is a concentration of 4.29 copies/μL or 4,290 copies/mL in the starting contrived patient sample.

12.2 Inclusivity (Analytical Sensitivity)

12.2.1 *In Silico* Inclusivity

Alignments have been performed with the oligonucleotide CoPrimer sequences of the COVID-19 CoPrimers with publicly available nucleic acid sequences for SARS-CoV-2 in the GenBank, NCBI, and GISAID databases to demonstrate the predicted inclusivity of the **Logix Smart COVID-19** test.

Co-Diagnostics has been performing consistent reviews of the sequence alignment to monitor the sequence conservation by analyzing phylogenetic mutation genomic data pulled by NextStrain from the GISAID database. The first alignment was performed on 1-Feb-2020 with the most recent query performed on 01-Mar-2023 (See Table 11). Sequences were analyzed at <https://nextstrain.org/ncov/gisaid/global>.

Table 11

Most Recent Monthly In Silico Assessment of NextStrain sequences from the GISAID database

Date of Analysis for CoDx's RdRp Marker	Strain	SARS-CoV-2 (sequences in analyzed subsample)	Sequences with 100% homology	Sequences with 1 mismatch (98% homology)	Sequences with 2 mismatches (95% homology)	Sequences with 3+ mismatches (<95% homology)
01-Mar-2023	BA.2, BA.2.75, BN.1, CH.1.1, XBB, XBB.1.5, XBC, XBF	1329	0 (0%)	1327 (99.85%)	2 (0.15%)	0 (0%)
	All Others	715	715 (100%)	0 (0%)	0 (0%)	0 (0%)

The alignment data and posterior updated analyses have shown 95% or greater homology on greater than 99% of publicly available SARS-CoV-2 strains throughout the pandemic for both the forward and reverse CoPrimers on the GISAID database. Therefore, there is <1% prediction of false-negative results, based upon the available data.

Additional in silico analyses have been performed on mutation data for each Variant of Concern (VOC) or Variant of Interest (VOI) lineage including all those displayed in Table 12. No VOC/VOI lineages contain characteristic mutations on the binding targets of our RdRp marker with the exception of the Delta Variant which has undergone further Wet-Test Inclusivity analysis (see section 12.2.2).

Table 12

SARS-CoV-2 Genomic Variants Classified as Variants of Concern or Interest (01-Mar-2023)

Variant of Concern / Interest Status by Agency	WHO Nomenclature	Pango Lineage	NextStrain Clade	Designation	First detected, Date
VOC [WHO, MHRA, ECDC, CDC]	Omicron	B.1.1.529, BA.1, BA.1.1, BA.2, BA.3, BA.4, BA.5, XE	21K, 21L, 21M, 22A, 22B, 22C, 22D	WHO: VOC 26NOV-2021 MHRA: VOC NOV-2021 ECDC: VOC 26NOV-2021 CDC: VOC 30NOV-2021	Multiple countries, Nov-2021
VOI [ECDC]	Omicron	BA.2.75, BQ.1, XBB, XBB.1.5	22D	ECDC: VOI SEP-2022	Multiple countries, May-2022, Jun-2022

Note: VOC – Variant of Concern, VOI – Variant of Interest, WHO – World Health Organization, MHRA – Medicines and Health Products Regulatory Agency (UK), ECDC – European Centre for Disease Prevention and Control, CDC – Centers for Disease Control and Prevention

12.2.2 Wet-Test Inclusivity

In the randomized contrived sample study run with the Genomic RNA of SARS-CoV-2, isolate USA-WA1/2020 (BEI Resources, catalog number NR-52285) all positive samples were detected showing 100% detection rate for SARS-CoV-2 (See Table 15).

The sensitivity of the **Logix Smart COVID-19** test toward Delta variant was empirically evaluated using synthetic RNA oligonucleotides containing either a perfect match Wild-Type (WT) sequence or the single nucleotide Mismatch from the Delta Variant and Delta-related hybrid variants. The acceptance criterion for the experiment was for the LoD of the Mismatch RNA Oligo to be ≤ 3 -fold the LoD of the WT RNA oligo. Both oligos were hydrated with 10% TE buffer to a stock concentration of 1E10 copies/ μ L, then serially diluted to 1,000, 100, 50, 25, 10, or 5 copies/ μ L for LoD Estimation. As shown in

Based on these analyses, the **Logix Smart COVID-19** test retains full sensitivity for lineages classified as Variants of Concern (VOC) and Variants of Interest (VOI) at this time, including Omicron and all of its existing subvariants (B.1.1.529, B.1.1.529.XE, BA.1, BA.1.1, BA.2, BA.3, BA.4, BA.5, B.A.2 + L452X, BA.2.12.1, B.A.2.75, BA.2.75.2, BA.4.6, BA.5.2.35, BF.7, BF.14, BN.1, BQ.1, BQ.1.1, BQ.1.1.20, CH.1.1, CH.1.1.1, CH.1.1.2, XBB, XBB.1.5, XBC, or XE), as well as other emerging variant sequences present in the monthly NextStrain sampling of the GISAID database.

Table 13, both RNA oligonucleotides were consistently detected down to 10 or 5 copies/ μ L, respectively. LoD Confirmation for both Oligos was performed at 10, 7.5, or 5 copies/ μ L. The LoDs of the WT and Mismatch Oligo were confirmed at 10 or 7.5 copies/ μ L, respectively, meeting the Acceptance Criterion to support retained sensitivity of the **Logix Smart COVID-19** test toward Delta variant and further corroborating the *in silico* analysis.

Based on these analyses, the **Logix Smart COVID-19** test retains full sensitivity for lineages classified as Variants of Concern (VOC) and Variants of Interest (VOI) at this time, including Omicron and all of its existing subvariants (B.1.1.529, B.1.1.529.XE, BA.1, BA.1.1, BA.2, BA.3, BA.4, BA.5, B.A.2 + L452X, BA.2.12.1, B.A.2.75, BA.2.75.2, BA.4.6, BA.5.2.35, BF.7, BF.14, BN.1, BQ.1, BQ.1.1, BQ.1.1.20, CH.1.1, CH.1.1.1, CH.1.1.2, XBB, XBB.1.5, XBC, or XE), as well as other emerging variant sequences present in the monthly NextStrain sampling of the GISAID database.

Table 13

Delta Variant Synthetic Oligonucleotide LoD Estimation and Confirmation Results

	copies/ μ L	Wild-Type RNA Oligo			Delta Variant RNA Oligo		
		Average Ct	S.D.	# Detected	Average Ct	S.D.	# Detected
LoD Estimation	10,000	26.14	0.08	2/2	25.50	0	2/2
	1,000	29.07	0.14	2/2	29.17	0.06	2/2
	100	33.06	0.16	4/4	32.64	0.33	4/4
	50	34.36	0.33	4/4	33.63	0.46	4/4

	25	35.08	0.88	4/4	35.27	0.40	4/4
	10	36.02	0.38	4/4	36.69	0.89	4/4
	5	36.50	0	1/2	37.61	0.43	2/2
LoD Confirmation	10	34.83	0.66	20/20	34.63	0.95	20/20
	7.5	37.00	1.12	17/20	36.51	0.84	20/20
	5	37.41	0.80	13/20	36.37	0.68	17/20

12.3 Cross-Reactivity (Analytical Specificity) By an In Silico Analysis

In silico Analysis and BLASTn analysis queries of the SARS-CoV-2 CoPrimers were performed against public domain nucleotide sequences. The database search parameters were as follows:

- The nucleotide collection consists of GenBank+EMBL+DDBJ+PDB+RefSeq sequences, but excludes EST, STS, GSS, WGS, and TSA patent sequences; phase 0, 1, and 2 HTGS sequences; and sequences longer than 100 Mb.
- The database is non-redundant. Identical sequences have been merged into one entry while preserving the accession, GI, title, and taxonomy information for each entry.
- The database is reviewed consistently to detect potential mutations in the targeted region.
- The search parameters automatically adjust for short input sequences and the expect threshold is 1000.
- The match and mismatch scores are 1 and -3, respectively.
- The penalty to create and extend a gap in alignment is 5 and 2 respectively.
- BLASTn was run individually for every organism requested by the FDA EUA pre-submission process (*in silico*) guidelines.

Table 14 displays the list of relevant microorganisms analyzed in the cross-reactivity *in silico* assessment.

No coronaviruses, other than SARS-CoV-2, or human microflora had any hits with <5 mismatches or >80% total homology that would predict potential false positive RT-PCR results.

CoPrimers have a slightly different cross-reactivity risk profile than traditional primers. Due to the low T_m's of the Priming and Capture sequences, CoPrimers are more susceptible to mismatches. Our internal experiments show that a single mismatch on either forward or reverse causes a noticeable delay in amplification, with more mismatches causing significant suppression of signal. Three or more

mismatches on the forward and reverse combined, are expected to result in no detectable amplification.

The results suggest that the **Logix Smart COVID-19** test does not cross-react to any of the non-target organisms that were tested in the wet test or *in silico* analysis. The negative samples did not show any amplification, therefore, no false positives occurred due to cross-reactivity. Positive samples in the presence of non-target organism genetic material in most cases did not reduce the ability of the **Logix Smart COVID-19** test to produce positive results.

Table 14

Microorganism Included in The Cross-Reactivity In Silico Assessment

High priority pathogens from the same genetic family	High priority organisms likely in the circulating area	Other microorganisms of importance
Human coronavirus 229E	Adenovirus	Influenza C
Human coronavirus OC43	Human Metapneumovirus (hMPV)	Parechovirus
Human coronavirus HKU1	Parainfluenza virus 1-4	<i>Corynebacterium diphtheriae</i>
Human coronavirus NL63	Influenza A & B	<i>Legionella non-pneumophila</i>
SARS-coronavirus	Enterovirus	<i>Bacillus anthracis</i> (Anthrax)
MERS-coronavirus	Respiratory syncytial virus	<i>Moraxella catarrhalis</i>
	Rhinovirus	<i>Neisseria elongata</i>
	<i>Chlamydia pneumoniae</i>	<i>Neisseria meningitides</i>
	<i>Haemophilus Influenza</i>	Leptospirosis
	<i>Legionella pneumophila</i>	<i>Chlamydia psittaci</i>
	<i>Mycobacterium tuberculosis</i>	<i>Coxiella burnetii</i> (Q-Fever)
	<i>Streptococcus pneumoniae</i>	<i>Staphylococcus aureus</i>
	<i>Streptococcus pyogenes</i>	
	<i>Bordetella pertussis</i>	
	<i>Mycoplasma pneumoniae</i>	
	<i>Pneumocystis jirovecii</i> (PJP)	
	<i>Pooled human nasal wash – to represent diverse microbial flora in</i>	

High priority pathogens from the same genetic family	High priority organisms likely in the circulating area	Other microorganisms of importance
	<i>the human respiratory tract</i>	
	<i>Candida albicans</i>	
	<i>Pseudomonas aeruginosa</i>	
	<i>Staphylococcus epidermidis</i>	
	<i>Staphylococcus salivarius</i>	

12.4 Microbial Interference

No microorganism in the *in silico* analysis has revealed $\geq 80\%$ homology between the cross-reactivity microorganisms, including the ones of relevance listed in Table 14, and the CoPrimers.

13 CLINICAL EVIDENCE

The clinical evidence was established by producing 180 randomized contrived samples spiked with the Genomic RNA of SARS-CoV-2, isolate USA-WA1/2020 (BEI Resources, catalog number NR-52285) in dilutions of 600, 1,000, 5,000, and 10,000 genomic copies per sample (sample input 140 μ L). The randomized contrived samples were extracted using the QIAamp Viral RNA Mini Kit (Qiagen, catalog number 52904/52906) and tested with **Logix Smart Coronavirus Disease 2019 (COVID-19)**. The detection rate for Logix Smart COVID-19 is shown in Table 15. Results also showed consistency of positive control results.

Table 15

Randomized Contrived Sample Detection Rate

Sample Concentration	# of Samples	# of Detected	% of Positive Results (Confidence Interval)	Mean Cq	SD (Standard Deviation)	CV% (Coefficient of Variance)
600 (genomic copies/extraction) ($\approx 1 \times$ LoD)	9	9	100 (CI 86.7 – 100)	33.21	0.57	1.7
1,000 (genomic copies/extraction) ($\approx 2 \times$ LoD)	51	51	100 (CI 86.7 – 100)	34.11	0.77	2.3
5,000 (genomic copies/extraction) ($\approx 9 \times$ LoD)	15	15	100 (CI 86.7 – 100)	31.63	0.34	1.1
10,000 (genomic copies/extraction) ($\approx 14 \times$ LoD)	15	15	100 (CI 86.7 – 100)	30.59	0.38	1.2
Negative Randomized Contrived Sample	90	0	0 (Not Applicable)	Not Applicable	0	0

14 MANUFACTURER AND AUTHORIZED REPRESENTATIVE

**Manufacturer:**

Co-Diagnostics, Inc.
2401 S Foothill Dr. Ste D
Salt Lake City, UT 84109
Phone: +1 (801) 438-1036
Email: info@co-dx.com
Website: www.co-dx.com

**Authorized Representative:**

mdi Europa GmbH
Langenhagener Str. 71
D-30855 Hannover-Langenhagen
Germany
Phone: +49 511 39 08 95 30
Email: info@mdi-europa.com
Website: www.mdi-europa.com

**Rx only**

15 REFERENCES

- CDC. (2009). *Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition*. Retrieved from CDC Laboratories: <https://www.cdc.gov/labs/BMBL.html>
- CDC. (2020, Feb 20). *Coronavirus Disease 2019 (COVID-19) - Information for Laboratories: Real-Time RT-PCR Resources*. Retrieved Mar 8, 2020, from Centers for Disease Control and Prevention: <https://www.cdc.gov/coronavirus/2019-ncov/lab/index.html>
- CDC. (2020, Feb 7). *Coronavirus Disease 2019 (COVID-19): Information for Laboratories*. Retrieved from Centers for Disease Control and Prevention: <https://www.cdc.gov/coronavirus/2019-ncov/downloads/processing-sputum-specimens.pdf>
- CDC. (2020, Feb 16). *Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)*. Retrieved September 15, 2018, from World Health Organization: https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Flab-biosafety-guidelines.html
- Centers for Disease Control and Prevention. (2017, Oct 27). *CDC Laboratory Training: Good Laboratory Practices for Molecular Genetics Testing*. Retrieved Mar 5, 2019, from CDC: <https://www.cdc.gov/labtraining/training-courses/good-lab-practices-molecular-genetics-testing.html>
- Poritz, M., & Ririe, K. (2014, Mar). Getting things backwards to prevent primer dimers. *Journal of Molecular Diagnosis*, 159-62. doi:10.1016/j.jmoldx.2014.01.001
- Satterfield, B. (2014, Mar). Cooperative primers: 2.5 million-fold improvement in the reduction of nonspecific amplification. *Journal of Molecular Diagnosis*, 163-73. doi:10.1016/j.jmoldx.2013.10.004
- Viana, R. V., & Wallis, C. L. (2011). Good Clinical Laboratory Practices (GLCP) for

Molecular Based Tests Used in Diagnostic Laboratories. In D. I. Akyar, *Wide Spectra of Quality Control* (pp. 29-52). InTech. Retrieved from <http://www.intechopen.com/books/wide-spectra-of-quality-control/goodclinical-laboratory-practice-gclp-for-molecular-based-tests-used-in-diagnostic-laboratories>

















WHO. (2004). *Laboratory Biosafety Manual*. Retrieved from Emergencies preparedness, response: https://www.who.int/csr/resources/publications/biosafety/WHO_CDS_CSR_LYO_2004_11/en/

16 LEGEND OF PACKAGE SYMBOLS

A legend of the package symbols is displayed in Table 16.

Table 16

Legend of Package Symbols

Icon	Description
	<i>In vitro</i> diagnostic medical device
	Catalog number
	Batch Code
	Cap color
	Component
	Content/Volume
	Number
	Use-by-date
	Contains sufficient for n tests/reactions
	Protect from light
	Temperature limit
	Consult Instructions for Use
	Non-Sterile product - Do not sterilize
	Manufacturer
	Authorized Representative in the European Community
	CE-Marking for IVD in compliance to EU Directive 98/79/EC
R only	For prescription use only